Literature DB >> 7603228

Remission of epilepsy: results from the National General Practice Study of Epilepsy.

O C Cockerell1, A L Johnson, J W Sander, Y M Hart, S D Shorvon.   

Abstract

Remission of seizures is a crucial measure of outcome in epilepsy. The National General Practice Study of Epilepsy (NGPSE) aimed to investigate the remission of patients with epilepsy and the effect of various factors on the likelihood of remission. The NGPSE is a prospective population-based study free from major selection bias. We enrolled 1091 patients with newly diagnosed or suspected epilepsy who attended one of 275 general practices throughout the UK between 1984 and 1987. Remission was analysed in those patients who were classified after 6 months as having definite epilepsy (n = 564) or possible epilepsy (n = 228). After 9 years from the index seizure, 86% (95% CI 81-90) of patients with definite epilepsy had achieved a remission of 3 years and 68% (61-75) a remission of 5 years. For the complete cohort, including those with possible epilepsy, the remission rates at 9 years were 87% (83-91) for 3-year remission and 71% (65-77) for 5-year remission. The proportion of patients with definite epilepsy who were still in remission at 9 years' follow-up (terminal remission) was 68% (62-74) for 3-year and 54% (48-60) for 5-year remission. 61% (56-68) of patients with idiopathic seizures and 61% (46-75) of those with remote symptomatic epilepsy had achieved 5-year remission by 9 years. Overall, age and seizure type had little effect on the chances of achieving remission. This study confirms the good outcome for seizure control in the majority of patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7603228     DOI: 10.1016/s0140-6736(95)91208-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  95 in total

Review 1.  Recent Advances. Neurology.

Authors:  A J Larner; S F Farmer
Journal:  BMJ       Date:  1999-08-07

2.  Anti-epileptic activity of Nelumbo nucifera fruit.

Authors:  Muhammad Ali Rajput; Rafeeq Alam Khan; Tahira Assad
Journal:  Metab Brain Dis       Date:  2017-08-03       Impact factor: 3.584

3.  Honing in on risk factors for prolonged remission off medication by reducing heterogeneity.

Authors:  Dale C Hesdorffer
Journal:  Epilepsy Curr       Date:  2012-05       Impact factor: 7.500

4.  Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.

Authors:  Simona Lattanzi; Francesco Brigo; Eugen Trinka; Gaetano Zaccara; Claudia Cagnetti; Cinzia Del Giovane; Mauro Silvestrini
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

Review 5.  Tiagabine add-on for drug-resistant partial epilepsy.

Authors:  Jennifer Pulman; Anthony G Marson; Jane L Hutton
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

6.  Surgery for epilepsy.

Authors:  Siobhan West; Sarah J Nevitt; Jennifer Cotton; Sacha Gandhi; Jennifer Weston; Ajay Sudan; Roberto Ramirez; Richard Newton
Journal:  Cochrane Database Syst Rev       Date:  2019-06-25

7.  Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nevitt; Maria Sudell; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2019-06-24

Review 8.  Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nevitt; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2019-07-31

9.  Vigabatrin add-on therapy for drug-resistant focal epilepsy.

Authors:  Rebecca Bresnahan; Myrsini Gianatsi; Melissa J Maguire; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2020-07-30

10.  The dynamics of drug treatment in epilepsy: an observational study in an unselected population based cohort with newly diagnosed epilepsy followed up prospectively over 11-14 years.

Authors:  S D Lhatoo; J W Sander; S D Shorvon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.